Saturday 17 October 2026
Export CRL’s income statement to Excel — free account
Charles River Laboratories International, Inc.
CRL Healthcare Diagnostics & Research
Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024. In the quarter to June 2026, revenue fell 2.72%, EPS fell 102.8%, free cash flow fell 12.2% and total debt rose 12.3%, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
299.77
6.47
−2.11%
Follow CRL
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 1,025.56 | 25.30 | 22.82 | 48.49 | 34.04 | 29.55 | 24.08 | 42.72 | 23.19 |
Piotroski F-Score |
5 | 4 | 5 | 6 | 4 | 6 | 4 | 5 | 5 | 4 |
P/S ratio |
2.46 | 2.34 | 2.91 | 2.79 | 5.35 | 4.23 | 2.84 | 2.39 | 2.83 | 2.14 |
Altman Z-Score |
2.40 | 2.44 | 2.74 | 2.56 | 3.55 | 3.23 | 2.43 | 2.28 | 2.90 | 2.24 |
P/FCF ratio |
19.07 | 18.91 | 32.84 | 37.63 | 35.62 | 32.58 | 21.87 | 18.02 | 22.30 | 13.75 |
Altman Z″-Score (non-manufacturers) |
1.80 | 2.24 | 2.52 | 2.17 | 1.84 | 1.99 | 1.70 | 1.74 | 2.38 | 1.81 |
Beneish M-Score |
(3.11) | (2.97) | (2.54) | (2.38) | (2.64) | (2.42) | (2.58) | (2.58) | (2.60) | (2.42) |
P/Operating CF |
67.02 | 59.52 | 54.31 | 47.27 | 82.66 | 89.47 | 41.20 | 38.77 | 42.29 | 30.33 |
P/B ratio |
3.12 | 2.74 | 3.33 | 3.72 | 7.46 | 5.84 | 4.55 | 4.11 | 5.02 | 4.29 |
Price to Tangible BV |
150.53 | 0.00 | 0.00 | 0.00 | 0.00 | 50.97 | 347.48 | 0.00 | 30.09 | 0.00 |
EV/Sales |
2.94 | 2.85 | 3.48 | 3.41 | 6.05 | 4.83 | 3.47 | 3.04 | 3.36 | 2.80 |
EV/EBITDA |
19.90 | 14.34 | 15.43 | 14.21 | 25.03 | 21.17 | 16.56 | 13.99 | 14.87 | 12.95 |
EV/Operating CF |
16.01 | 15.70 | 21.02 | 21.90 | 28.14 | 25.86 | 18.91 | 15.64 | 19.60 | 14.88 |
EV/FCF |
22.78 | 22.99 | 39.34 | 46.02 | 40.24 | 37.19 | 26.71 | 22.91 | 26.46 | 18.02 |
Quick Ratio |
0.82 | 0.92 | 1.00 | 0.90 | 0.86 | 1.01 | 1.06 | 1.20 | 1.28 | 1.12 |
Current Ratio |
1.29 | 1.41 | 1.52 | 1.32 | 1.23 | 1.43 | 1.44 | 1.61 | 1.78 | 1.53 |
Net Debt/EBITDA |
3.24 | 2.54 | 2.55 | 2.59 | 2.83 | 2.62 | 3.00 | 2.99 | 2.34 | 3.07 |
Debt/Assets |
29.94% | 29.76% | 32.30% | 35.61% | 37.92% | 36.06% | 40.24% | 43.26% | 39.08% | 45.54% |
Debt/Equity |
0.67 | 0.65 | 0.73 | 0.91 | 1.05 | 0.93 | 1.15 | 1.26 | 1.09 | 1.47 |
Asset Turnover |
0.55 | 0.52 | 0.52 | 0.54 | 0.57 | 0.57 | 0.61 | 0.67 | 0.66 | 0.70 |
Operating CF/Net income |
(5.11) | 71.34 | 1.44 | 1.27 | 1.95 | 1.50 | 1.91 | 1.95 | 2.58 | 2.05 |
Capex/Depreciation |
(0.39) | (0.40) | (1.01) | (1.07) | (0.86) | (0.71) | (0.71) | (0.87) | (0.63) | (0.44) |
Interest Coverage |
0.24 | 1.80 | 4.52 | 10.98 | 7.98 | 5.01 | 5.77 | 5.20 | 9.68 | 8.57 |
| (4.35%) | 0.29% | 14.42% | 17.62% | 16.79% | 19.40% | 17.04% | 19.13% | 13.08% | 19.63% | |
| (1.97%) | 0.13% | 6.01% | 6.65% | 6.25% | 7.15% | 5.90% | 6.67% | 4.37% | 6.48% | |
ROIC |
0.31% | 2.58% | 6.46% | 7.46% | 7.43% | 6.99% | 6.67% | 7.42% | 8.88% | 7.59% |
Return on Tangible Assets |
(7.28%) | 0.51% | 21.64% | 26.82% | 25.52% | 24.52% | 18.60% | 17.79% | 10.77% | 15.74% |
Average Days of Receivables |
64.44 | 64.97 | 68.98 | 69.07 | 66.28 | 77.11 | 71.58 | 76.07 | 84.49 | 79.03 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
18.51% | 18.54% | 18.11% | 16.73% | 17.51% | 18.09% | 19.75% | 19.59% | 19.99% | 21.69% |
Intangible Assets out of Total Assets |
0.44 | 0.47 | 0.48 | 0.50 | 0.54 | 0.34 | 0.34 | 0.34 | 0.30 | 0.32 |
Share Based Compensation of Revenue |
1.77% | 1.73% | 1.74% | 1.85% | 2.02% | 1.93% | 2.18% | 2.09% | 2.37% | 2.60% |
Graham Net Nets |
(0.25) | (0.28) | (0.25) | (0.29) | (0.17) | (0.18) | (0.27) | (0.30) | (0.20) | (0.34) |
Graham Number |
0.00 | 16.53 | 121.04 | 112.40 | 93.95 | 84.02 | 62.53 | 53.95 | 35.85 | 36.40 |
Earnings Yield |
(1.48%) | 0.10% | 3.95% | 4.38% | 2.06% | 2.94% | 3.38% | 4.15% | 2.34% | 4.31% |
Free Cash Flow Yield |
5.24% | 5.29% | 3.04% | 2.66% | 2.81% | 3.07% | 4.57% | 5.55% | 4.49% | 7.27% |
Revenue per Share |
81.01 | 78.82 | 80.61 | 78.25 | 70.39 | 59.01 | 53.79 | 47.26 | 39.12 | 35.76 |
Operating CF per Share |
14.88 | 14.30 | 13.35 | 12.19 | 15.13 | 11.03 | 9.87 | 9.20 | 6.70 | 6.74 |
Capex per Share |
(4.42) | (4.53) | (6.22) | (6.39) | (4.55) | (3.36) | (2.88) | (2.92) | (1.74) | (1.18) |
Free Cash Flow per Share |
10.46 | 9.76 | 7.13 | 5.80 | 10.58 | 7.67 | 6.99 | 6.28 | 4.96 | 5.56 |
Cash per Share |
4.31 | 3.79 | 5.40 | 4.60 | 4.80 | 4.61 | 4.88 | 4.08 | 3.45 | 2.50 |
Shareholders Equity per Share |
63.96 | 67.48 | 70.32 | 58.67 | 50.48 | 42.75 | 33.61 | 27.53 | 22.06 | 17.85 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
63.96 | 67.48 | 70.32 | 58.67 | 50.48 | 42.75 | 33.61 | 27.53 | 22.06 | 17.85 |
Free Cash Flow |
518.49 | 501.61 | 365.37 | 294.91 | 532.03 | 380.02 | 340.42 | 301.09 | 235.64 | 261.61 |
Working Capital |
326.73 | 408.97 | 553.58 | 347.45 | 240.91 | 361.38 | 311.14 | 339.61 | 363.12 | 227.24 |
Capital Expenditures |
(219.15) | (232.97) | (318.53) | (324.73) | (228.77) | (166.56) | (140.51) | (140.05) | (82.43) | (55.29) |
Net Current Asset Value |
(2,518.44) | (2,658.32) | (2,984.06) | (3,182.66) | (3,211.21) | (2,171.53) | (2,033.64) | (1,638.26) | (1,055.89) | (1,215.84) |
EV/EBIT |
469.42 | 50.73 | 23.28 | 20.85 | 36.29 | 32.66 | 25.90 | 20.82 | 21.63 | 19.85 |
Capex to Sales |
0.05 | 0.06 | 0.08 | 0.08 | 0.06 | 0.06 | 0.05 | 0.06 | 0.04 | 0.03 |
Price to Operating Income |
392.93 | 41.72 | 19.44 | 17.05 | 32.13 | 28.61 | 21.20 | 16.38 | 18.22 | 15.15 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.34 | 0.36 | 0.19 | 0.21 | 0.21 | 0.21 | 0.19 | 0.17 | 0.17 | 0.17 |
Cash ROIC |
9.39% | 8.50% | 5.60% | 4.98% | 9.77% | 8.78% | 9.04% | 9.46% | 10.00% | 11.94% |
Accounts Receivable Turnover |
5.62 | 5.40 | 5.39 | 5.70 | 5.62 | 5.17 | 5.32 | 5.02 | 4.68 | 5.30 |
Accounts Payable Turnover |
18.62 | 17.58 | 14.02 | 12.44 | 13.76 | 15.82 | 18.71 | 19.79 | 15.81 | 19.73 |
Inventory Turnover |
9.32 | 8.25 | 8.26 | 11.05 | 11.46 | 10.68 | 11.53 | 11.74 | 10.97 | 10.95 |
Average Days of Payables |
20.17 | 18.84 | 23.47 | 29.90 | 32.79 | 24.16 | 24.47 | 16.96 | 24.56 | 24.09 |
Days of Inventory on Hand |
40.55 | 37.40 | 52.84 | 37.15 | 32.96 | 36.63 | 35.26 | 32.73 | 36.28 | 33.72 |
Average Receivables |
714.89 | 750.65 | 766.38 | 697.64 | 630.31 | 565.89 | 493.14 | 451.13 | 397.03 | 317.06 |
Average Payables |
144.57 | 154.64 | 187.43 | 202.02 | 160.30 | 116.99 | 88.87 | 72.04 | 73.16 | 52.58 |
Average Inventory |
288.82 | 329.40 | 318.03 | 227.48 | 192.42 | 173.18 | 144.28 | 121.42 | 105.39 | 94.78 |
Average Assets |
7,331.88 | 7,861.67 | 7,898.89 | 7,313.53 | 6,257.56 | 5,091.81 | 4,274.33 | 3,392.90 | 2,820.86 | 2,390.15 |
Average Common Equity |
3,318.44 | 3,534.61 | 3,291.68 | 2,760.03 | 2,328.58 | 1,878.00 | 1,478.80 | 1,183.59 | 943.27 | 788.34 |
Columns are period end dates